GILD
Gilead Sciences
Biological Products, (No Diagnostic Substances) · Health Care
$167.47-1.68%
Quote via Yahoo Finance, may be delayed · 2026-11-03 · 4:00 PM ET
Daily prices: Yahoo Finance, split-adjusted. As of 2026-11-03.
Drag across the line to read a price. Dots mark earnings, filings and dividends.
Mixed profile
Operating margin lifts this profile the most.
As of 2025-12-31. Latest quarter ended 2026-09-30. v1 methodology, subject to change.
The profile score is 16 points higher since last quarter. Profits is 36 points higher. Debt and safety is 23 points higher.
Sector rank 5 of 46
In plain English
- Gilead Sciences operates in Biological Products, (No Diagnostic Substances).
- Latest-year revenue was 29.4 billion.
- The profile score is 63, a Mixed profile. Profits is the strongest listed input.
Written from the figures on this page. No language model was called. It may still be wrong. Not advice.
As of 2025-12-31. Latest quarter ended 2026-09-30. SEC EDGAR companyfacts, fetched 2026-11-01. SEC filing
Financials
Tap a column to read the value.
P/E vs own history
Now 24.7 times, 5-year median 18.9 times.
Line is the quarterly multiple. The band is the 25th to 75th percentile of that history. The dashed line is the median.
Earnings
Actual earnings per share from EDGAR filings. Historical estimates are not used.
Actual from EDGAR
Data confidence
The Company Score summarises financial characteristics relative to similar companies using a published formula. It does not predict future returns.
SEC EDGAR companyfacts, fetched 2026-11-01.